Equity Profile
Pre-Earnings Brief
Illumina Inc (ILMN) is a leading company in the health care sector, specializing in life sciences tools and services. They focus on genomic sequencing technologies, which are crucial for advancements in personalized medicine and genetic research.
EPS
Earnings per share is a key indicator of profitability and is closely watched by investors.
Revenue
Revenue figures provide insight into the company's sales performance and market demand.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+139.77%
Avg Stock Reaction
+0.69%
In Q4 2025, Illumina reported an EPS of $1.35, exceeding expectations by 7.4%. However, the stock experienced a slight decline the following day.
Management Promises & Guidance
Analysts are generally optimistic about Illumina's upcoming earnings, expecting solid performance based on historical trends.
Bull Case
If Illumina beats EPS estimates, it could reinforce confidence in its growth strategy and lead to a positive stock reaction.
Bear Case
A miss on earnings could raise concerns about market demand and competitive pressures, potentially leading to a negative stock response.
EPS
$1.05Earnings per share is a key indicator of profitability and is closely watched by investors.
Revenue
$1.1BRevenue figures provide insight into the company's sales performance and market demand.
Expectations
The print will turn on these two things.
Q1
Will Illumina's EPS exceed the consensus estimate of $1.05?
A beat could indicate strong operational performance and boost investor confidence.
Q2
What insights will management provide regarding revenue growth and market demand?
Understanding revenue trends is critical for assessing the company's future prospects.
Edge
Why consensus could be wrong
The market may be underestimating Illumina's ability to innovate and capture market share, especially in emerging genomic applications.
Supporting Evidence
Illumina has consistently beaten EPS estimates, indicating strong operational execution.
Recent advancements in genomic technology may drive higher demand than currently anticipated.
The company's focus on R&D could lead to new products that outperform market expectations.
Key Risk
If revenue growth shows signs of slowing, it could challenge the optimistic consensus.
Edge
Pre-commit to what would confirm each case.
This quarter's performance is crucial as it reflects the company's ability to navigate market challenges and maintain growth.
Bull Confirmed If
Earnings exceeding $1.05 with revenue at or above $1.1B would confirm the bullish outlook.
Bear Confirmed If
Earnings below $1.05 or revenue significantly under $1.1B would support the bearish case.
Pre-Earnings Positioning
Implied Move
±4.2%
Historical Avg
±2.2%
The options market is pricing in a moderate move, suggesting uncertainty around the earnings report.
Options are pricing ±5.1% while ILMN has averaged ±2.2% over the last 8 prints — setup is pricing rich.
30d HV
36.5%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Illumina beats expectations, history suggests a potential stock increase of around 0.69%, confirming positive sentiment.
In-Line / Cautious
An in-line report could lead to a muted reaction as investors await further guidance from management.
Miss
A miss could result in a decline, with historical patterns indicating a potential drop of around 2.23%.
Preparation
House & Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
Net buying
Recent Transactions
Traded Feb 10, 2026 · disclosed Mar 9, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AVALONBAY CMNTYS INC REIT